Interim report January – March 2021
The period in summary
First quarter January 1 – March 31, 2021
· The regulatory process for the Company’s Marketing Authorization Application (MAA) for Strangvac in Europe has proceeded according to plan. On January 12th Intervacc submitted the responses to the Day 120 questions to the European Medicines Agency (EMA). The Company estimates that it is on track for a positive opinion during Q2 2021. · The study "Globetrotting strangles: the unbridled national and international transmission of Streptococcus equi between horses" was published in the scientific journal Microbial